Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILE: Dapagliflozin in Women with Non-obstructive Coronary Artery Disease
NCT05762952Phase 1Recruiting
- Sponsor
- University of Virginia
- Start
- Jun 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Myocardial ischemia (MI) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in myocardial perfusion reserve at 12 weeks. Started Jun 2023; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
Myocardial ischemia (MI)
Beyond the preview
Go deeper on NCT05762952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05762952.